Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Why Clovis Oncology's Shares Were Decimated

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of oncology-focused biopharmaceutical company Clovis Oncology (Nasdaq: CLVS  ) were hammered on Monday, falling nearly 42%, following the release of disappointing clinical data for the company's metastatic pancreatic cancer drug, CO-101.

So what: Details of the LEAP trial were released this morning, showing that Clovis' CO-101 had no difference in overall survival when compared to the current standard of treatment, Gemzar, made by Eli Lilly (NYSE: LLY  ) . Both drugs boasted a median survival rate of six months, and, according to its CEO, Patrick Mahaffy during a conference call following the news release (and via Reuters), the results were "even more ambiguous than we could have imagined." Subsequently, Clovis has halted development of CO-101 and will instead focus on CO-1686, its early stage experimental lung cancer treatment, which should have data out in the first half of 2013.

Now what: If that wasn't enough of a kick in the pants, after the bell on Friday, Celgene (Nasdaq: CELG  ) released its earnings results along with a study showing that its cancer blockbuster Abraxane, when combined with Lilly's Gemzar, improved survival rates in patients with pancreatic cancer. Clovis does have one thing going for it: $6.78 in cash per share with no debt; however, even that balance is slowly dwindling because of clinical trial expenses. For now, I'm perfectly happy keeping my distance from Clovis following today's train wreck.

Craving more input? Start by adding Clovis Oncology to your free and personalized watchlist so you can keep up on the latest news with the company.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2108108, ~/Articles/ArticleHandler.aspx, 10/22/2016 11:33:29 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:00 PM
CELG $98.91 Down -1.11 -1.11%
Celgene CAPS Rating: *****
CLVS $34.24 Down -0.23 -0.67%
Clovis Oncology CAPS Rating: ***
LLY $78.25 Down -0.49 -0.62%
Eli Lilly and Co. CAPS Rating: ***